Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan
Eisai Co., Ltd. announced that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment of Alzheimer’s disease from the Japanese Ministry of Health, Labour and Welfare. The new oral jelly formulation is easier for patients with Alzheimer’s disease who have difficulty swallowing to take and is the first treatment of its kind in the world.
Aricept® is an acetylcholinesterase inhibitor developed by Eisai, which works to increase levels of acetylcholine, a neurotransmitter, in the brain. It is the only approved treatment for Alzheimer’s disease in Japan, and is used in the treatment of patients with mild to severe forms of the disease.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer - Appointment to drive Zelluna through next stage of international clinical-phase development
Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals
Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents
Cardio3 BioSciences Receives ISO-13485 Certification
Gene Logic Expands International Operations - Establishes Staff in UK and Germany - Forms Gene Logic K.K. to Serve Japanese Market

New way in which insulin interacts with its receptor discovered
Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's
